Module 9 - Part 3 of 7

Pharmaceutical Patents

Master India's unique approach to pharmaceutical patents - from the groundbreaking Section 3(d) efficacy standard to compulsory licensing, Bolar exception, and the global debate on access to medicines. Understand how India balances innovation incentives with public health needs.

Duration: 90-120 minutes
8 Key Topics
10 Quiz Questions
Topic 1

Section 3(d) Analysis in Detail

Section 3(d) of the Indian Patents Act is one of the most significant provisions in global pharmaceutical patent law. It addresses the phenomenon of "evergreening" - the practice of seeking patents on minor modifications to extend monopoly periods beyond the original patent term.

Section 3(d) - Patents Act, 1970

"The following are not inventions within the meaning of this Act:

(d) the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance or the mere discovery of any new property or new use for a known substance or of the mere use of a known process, machine or apparatus unless such known process results in a new product or employs at least one new reactant.

Explanation: For the purposes of this clause, salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substance shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy."

Breaking Down Section 3(d)

"New form of a known substance"
Includes polymorphs, salts, esters, ethers, metabolites, isomers, particle sizes, and other derivatives. These modified forms are presumed to be the "same substance" as the original.
"Enhancement of known efficacy"
The key test. The new form must demonstrate significantly enhanced therapeutic efficacy - not just improved physicochemical properties like stability, bioavailability, or solubility. The Novartis case clarified this requires therapeutic enhancement.
"New property or new use"
Discovery of new properties or uses of known substances is excluded. Second medical use claims (same compound, different disease) face significant hurdles under this provision.
"Differ significantly in properties with regard to efficacy"
The burden is on the applicant to demonstrate significant difference in efficacy. Statistical significance in clinical or pre-clinical data may be required.
Key Concept: Efficacy Standard

The Supreme Court in Novartis clarified that "efficacy" in Section 3(d) means "therapeutic efficacy" for pharmaceutical substances. This requires demonstrating that the new form actually works better as a medicine - reducing symptoms, curing disease, or improving patient outcomes. Improvements in manufacturing convenience, stability, or bioavailability alone do not satisfy Section 3(d) unless they translate to better therapeutic outcomes.

Topic 2

Evergreening Concerns and Public Health

Section 3(d) was specifically designed to prevent "evergreening" - a strategy where pharmaceutical companies extend patent monopolies through incremental modifications rather than genuine innovation. Understanding this context is essential for appreciating the provision's public health rationale.

What is Evergreening?

Evergreening refers to strategies used to extend effective patent protection beyond the original 20-year term:

  • Polymorph patents: Patenting different crystalline forms of the same molecule
  • Salt form patents: Patenting different salt versions (hydrochloride, mesylate, etc.)
  • Formulation patents: Patenting new delivery mechanisms or dosage forms
  • Metabolite patents: Patenting active metabolites of original drugs
  • Combination patents: Combining known drugs into single formulations
  • Second medical use: Patenting same compound for different therapeutic indications

Public Health Impact

Evergreening has significant public health implications, particularly in developing countries:

  • Delayed Generic Entry: Extends monopoly pricing beyond original patent expiry
  • Access to Medicines: Keeps life-saving drugs expensive longer
  • Innovation Incentives: Rewards incremental modification over breakthrough innovation
  • Resource Allocation: Diverts R&D from novel compounds to modifications
Case Study: Novartis AG v. Union of India (Supreme Court, 2013)

Facts: Novartis sought a patent for Gleevec (imatinib mesylate) - a groundbreaking cancer drug. However, the patent application was for the beta crystalline form of imatinib mesylate, not the original imatinib. The original compound was known from a 1993 patent (which had expired). Novartis argued the beta crystalline form had enhanced bioavailability (30% improvement).

Issue: Whether the beta crystalline form of imatinib mesylate demonstrated "enhanced efficacy" under Section 3(d).

Held: The Supreme Court denied the patent, holding that:

  • "Efficacy" in Section 3(d) for pharmaceutical substances means "therapeutic efficacy"
  • Enhanced bioavailability alone does not establish enhanced therapeutic efficacy
  • Novartis failed to demonstrate that the beta crystalline form was therapeutically superior to the free base or other forms
  • Section 3(d) is TRIPS-compliant as it sets a standard for novelty/inventive step

Significance: This landmark decision established that Section 3(d) requires proof of enhanced therapeutic efficacy, setting a high bar for pharmaceutical patents on modified forms. The decision has been hailed as protecting access to medicines while criticized by innovator pharma companies.

Post-Novartis Landscape

The Novartis decision has significantly influenced pharmaceutical patenting in India:

  • Applicants must provide comparative efficacy data
  • Claims for polymorphs and salts face heightened scrutiny
  • Generic competition enters earlier for many drugs
  • India maintains position as "pharmacy of the developing world"
Topic 3

Compulsory Licensing (Natco v. Bayer)

Compulsory licensing allows governments to authorize production of patented products without the patent holder's consent. India's compulsory licensing provisions, based on TRIPS flexibilities, became globally significant with the Natco v. Bayer case - the first compulsory license granted in India.

Section 84 - Compulsory Licenses

At any time after three years from the date of grant of a patent, any person interested may apply for a compulsory license on any of the following grounds:

  • (a) The reasonable requirements of the public with respect to the patented invention have not been satisfied; or
  • (b) The patented invention is not available to the public at a reasonably affordable price; or
  • (c) The patented invention is not worked in the territory of India.
Landmark Case: Natco Pharma Ltd. v. Bayer Corporation (Controller of Patents, 2012)

Background: Bayer held a patent for Sorafenib (Nexavar), a cancer drug for kidney and liver cancer. Bayer priced the drug at approximately Rs. 2.8 lakh per month (about $5,500). Natco Pharma applied for a compulsory license to manufacture a generic version.

Findings on Section 84 Grounds:

  • Reasonable requirements not satisfied: Bayer supplied only 2% of the 8,842 patients estimated to need the drug
  • Not reasonably affordable: At Rs. 2.8 lakh/month, the drug was beyond reach of most patients
  • Not worked in India: Bayer imported the drug rather than manufacturing in India

Terms of Compulsory License:

  • Natco could manufacture and sell generic Sorafenib at Rs. 8,800/month (97% price reduction)
  • Natco to pay 6% royalty to Bayer
  • Natco to supply free to 600 patients annually
  • License non-exclusive and non-assignable

IPAB Confirmation (2013): Upheld the compulsory license grant, increasing royalty to 7%.

Other Compulsory License Grounds

Section 92 - National Emergency/Extreme Urgency
Government can issue compulsory license during national emergency, extreme urgency, or for public non-commercial use. No need to wait three years or attempt voluntary license.
Section 92A - Export to Countries with Insufficient Manufacturing
Compulsory license for export to countries lacking manufacturing capacity, implementing the WTO Doha waiver mechanism. Important for supplying generic AIDS drugs to Africa.
Key Concept: TRIPS Compliance

India's compulsory licensing provisions are fully compliant with TRIPS Article 31, which permits compulsory licensing subject to conditions: case-by-case determination, prior negotiation attempt (except in emergencies), limited scope and duration, predominantly for domestic market, adequate remuneration, and judicial review. The Doha Declaration (2001) affirmed that TRIPS flexibilities include compulsory licensing for public health purposes.

Topic 4

Data Exclusivity Debate

Data exclusivity (also called regulatory data protection) is a controversial issue in pharmaceutical IP that goes beyond patents. It refers to protection of clinical trial data submitted to regulatory authorities, preventing generic manufacturers from relying on that data for a specified period.

What is Data Exclusivity?

When an originator company seeks regulatory approval for a new drug, it submits extensive clinical trial data demonstrating safety and efficacy. Data exclusivity prevents regulatory authorities from:

  • Relying on originator's data to approve generic versions
  • Accepting "bioequivalence" applications during exclusivity period
  • Effectively blocking generic approval even if no patent exists

International Context

  • USA: 5 years for new chemical entities; 3 years for new clinical studies; 12 years for biologics
  • EU: 8+2+1 system (8 years data protection, 2 years market protection, 1 year for new indication)
  • TRIPS Article 39.3: Requires protection against "unfair commercial use" - but does not mandate exclusivity periods

Indian Position

India has resisted adopting data exclusivity:

  • No statutory data exclusivity: Indian law does not provide for regulatory data protection periods
  • Drugs and Cosmetics Act: Allows approval of generics based on bioequivalence studies
  • Policy rationale: Data exclusivity would block generics even when patents don't exist or have expired
  • Pressure in FTAs: US and EU have pushed for data exclusivity in trade negotiations
Key Concept: Data Exclusivity vs. Patents

Data exclusivity is separate from and additional to patent protection. A drug might have: (1) No patent (generic can manufacture) but data exclusivity blocks regulatory approval, or (2) Patent protection but compulsory license granted - data exclusivity could still block the generic. Critics argue data exclusivity is "TRIPS-plus" protection not required by international law and harmful to generic competition and access to medicines. India's refusal to adopt data exclusivity has been crucial for maintaining generic drug access.

Topic 5

Bolar Exception (Section 107A)

The "Bolar exception" or "regulatory review exception" allows generic manufacturers to conduct experiments and prepare regulatory submissions for patented drugs before patent expiry, enabling faster market entry once protection ends.

Section 107A - Certain Acts Not to Be Considered as Infringement

For the purposes of this Act, the following acts shall not be considered as infringement:

(a) any act of making, constructing, using, selling or importing a patented invention solely for uses reasonably related to the development and submission of information required under any law for the time being in force, in India, or in a country other than India, that regulates the manufacture, construction, use, sale or import of any product;

(b) importation of patented products by any person from a person who is duly authorised under the law to produce and sell or distribute the product, shall not be considered as infringement of patent rights.

Origin of the Bolar Exception

The exception derives from the US case Roche Products Inc. v. Bolar Pharmaceutical (1984), where the court initially held that using patented drugs for regulatory testing was infringement. Congress reversed this with the Hatch-Waxman Act (1984), creating the research exemption for regulatory submissions.

Scope in India

Section 107A(a) permits:

  • Making: Manufacturing batches for testing and regulatory samples
  • Constructing: Setting up production facilities and processes
  • Using: Conducting bioequivalence and stability studies
  • Selling: Providing samples to regulatory authorities
  • Importing: Bringing in API or samples for testing
Case Study: Bayer Corporation v. Union of India (Delhi High Court, 2010)

Facts: Bayer challenged Cipla's preparation to manufacture generic Sorafenib, arguing that Cipla was manufacturing commercial quantities during patent term.

Issue: What activities are covered by Section 107A(a)?

Held: The court gave a broad interpretation to Section 107A(a), holding that activities reasonably related to regulatory submissions - including manufacturing test batches and conducting bioequivalence studies - are not infringement. The exception applies to submissions in India or abroad.

Significance: Confirmed India's generous Bolar exception enables generic companies to prepare for market entry during the patent term.

Section 107A(b) - Parallel Imports

This provision permits parallel importation - importing genuine products sold abroad by the patentee or licensee. India follows the "international exhaustion" doctrine, meaning once a product is legitimately sold anywhere in the world, patent rights are exhausted and the product can be imported into India.

Topic 6

COVID-19 and IP Waiver (TRIPS Waiver)

The COVID-19 pandemic brought pharmaceutical IP issues to global attention, particularly regarding vaccine access. India, along with South Africa, led the proposal for a temporary TRIPS waiver for COVID-19 health products.

The India-South Africa TRIPS Waiver Proposal (October 2020)

India and South Africa proposed a temporary waiver of certain TRIPS provisions for COVID-19 prevention, containment, and treatment. The proposal covered:

  • Patents on vaccines, therapeutics, and diagnostics
  • Copyright on clinical trial data and software
  • Industrial designs for medical equipment
  • Trade secrets including manufacturing know-how

Arguments For the Waiver

  • Access Crisis: Vaccines concentrated in wealthy countries; developing nations faced severe shortages
  • Production Capacity: IP barriers prevented scaling up manufacturing globally
  • Public Funding: COVID vaccines were largely publicly funded - should be public goods
  • Precedent: Doha Declaration recognized public health emergencies justify TRIPS flexibilities

The WTO Decision (June 2022)

After extended negotiations, WTO members adopted a limited decision:

  • Waiver limited to patents on COVID-19 vaccines only (not therapeutics or diagnostics)
  • Developing country members (excluding China) can authorize production without rightholder consent
  • No need for case-by-case negotiation or adequate remuneration determination
  • Products under the waiver can be exported to eligible members
  • Duration: 5 years, subject to extension
Key Concept: Lessons for Future Pandemics

The COVID-19 TRIPS waiver debate highlighted several issues: (1) Existing TRIPS flexibilities (compulsory licensing) were insufficient for rapid pandemic response; (2) Technology transfer and manufacturing know-how are as important as legal permissions; (3) Global supply chains and export restrictions matter as much as IP; (4) Preparedness requires pre-negotiated mechanisms, not crisis-time negotiations. India's role in the waiver proposal reinforced its position as a champion of access to medicines in international IP negotiations.

Topic 7

Biologics and Biosimilars

Biologics - drugs derived from living cells - represent a growing share of the pharmaceutical market and present unique IP challenges different from traditional small-molecule drugs.

What Are Biologics?

Biologics are large, complex molecules produced by living cells:

  • Monoclonal antibodies: e.g., Trastuzumab (Herceptin), Rituximab
  • Therapeutic proteins: e.g., Insulin, Erythropoietin
  • Vaccines: Including COVID-19 mRNA vaccines
  • Gene therapies: Emerging category of advanced biologics

Biosimilars vs. Generics

Generic Small Molecules
Chemically identical to original. Proven through chemical analysis and bioequivalence studies. Relatively straightforward approval pathway.
Biosimilars
Highly similar but not identical to original biologic. Require extensive comparative clinical trials. More complex and expensive development. Process variations affect product.

Indian Biosimilar Framework

India has emerged as a significant biosimilar manufacturer:

  • CDSCO Guidelines (2016): Regulatory pathway for similar biologics
  • Abbreviated pathway: Reduced clinical trial requirements compared to originator
  • No data exclusivity: Biosimilar approval not blocked by regulatory data protection
  • Patent considerations: Complex patent landscapes around biologics (manufacturing processes, formulations, dosing regimens)
Case Study: Roche v. Biosimilar Manufacturers (India)

Roche's Trastuzumab (Herceptin) faced biosimilar competition in India earlier than most markets. Multiple Indian companies (Biocon, Mylan) developed biosimilar versions. Key issues included:

  • Patent status of various aspects of the product and process
  • Regulatory pathway for biosimilar approval
  • Price differential (biosimilars typically 30-40% cheaper)
  • Physician and patient acceptance

India's biosimilar market demonstrates how Section 3(d) and absence of data exclusivity enable earlier competition for biologics.

Topic 8

Indian Pharma IP Landscape

India's pharmaceutical industry is uniquely positioned - the world's largest supplier of generic medicines while also developing innovative capabilities. Understanding the overall IP landscape is essential for practitioners.

India: Pharmacy of the World

  • Generic Dominance: 20% of global generic exports; 60% of global vaccines
  • Affordable Medicines: Generic antiretrovirals transformed HIV/AIDS treatment access globally
  • Manufacturing Scale: Over 3,000 pharma companies; 10,500+ manufacturing units
  • TRIPS Transition: Product patents for pharmaceuticals only from 2005

Key Patent Challenges

Major pharmaceutical patents face scrutiny in India:

Pre-Grant Opposition (Section 25(1))
Any person can oppose patent grant before it is granted. Widely used for pharmaceutical patents - approximately 80% of pre-grant oppositions are for pharma patents.
Post-Grant Opposition (Section 25(2))
Any interested person can oppose within one year of grant. Has been used to revoke significant pharmaceutical patents.
Revocation Proceedings (Section 64)
Patents can be revoked by High Court or IPAB (now Appellate Board). Grounds include Section 3(d) non-compliance, lack of inventive step, insufficient disclosure.

Emerging Innovation

Indian pharma is evolving from pure generics toward innovation:

  • NCE Development: Companies like Sun Pharma, Dr. Reddy's pursuing novel molecules
  • Biosimilars: Biocon, Intas emerging as global biosimilar leaders
  • Contract Research: CROs supporting global pharma R&D
  • Patent Filing: Increasing domestic patent applications
Practitioner Guidance: Pharma Patent Strategy in India
  • For originator companies: Prepare robust Section 3(d) analysis with therapeutic efficacy data
  • Anticipate pre-grant opposition - common for significant pharma patents
  • Monitor compulsory license risk factors: pricing, availability, local manufacturing
  • For generic companies: Conduct thorough freedom-to-operate analysis
  • Utilize Bolar exception for early development activities
  • Consider timing of ANDA filing vis-a-vis Indian patent status
  • For biosimilars: Navigate complex patent landscapes and regulatory requirements
Test Your Knowledge

Part 3 Quiz

Answer the following 10 questions to test your understanding of Pharmaceutical Patents.

Question 1 of 10
Under Section 3(d), to obtain a patent on a new form of a known substance, the applicant must demonstrate:
  • A) Improved bioavailability
  • B) Enhanced therapeutic efficacy
  • C) Better stability
  • D) Novel polymorphic structure
Explanation:
The Supreme Court in Novartis clarified that "efficacy" in Section 3(d) for pharmaceutical substances means "therapeutic efficacy" - the drug must work better as a medicine. Improved bioavailability, stability, or novel structure alone are insufficient unless they translate to better therapeutic outcomes.
Question 2 of 10
In Novartis v. Union of India (2013), the Supreme Court denied the patent for Gleevec because:
  • A) Imatinib was already in the public domain
  • B) Novartis failed to conduct clinical trials in India
  • C) The patent term had already expired
  • D) The beta crystalline form did not demonstrate enhanced therapeutic efficacy over the known substance
Explanation:
The Supreme Court held that while Novartis showed 30% improved bioavailability for the beta crystalline form, this did not establish enhanced therapeutic efficacy. The new form was considered the "same substance" under Section 3(d) as it did not differ significantly in properties with regard to efficacy.
Question 3 of 10
Under Section 84, a compulsory license can be applied for after:
  • A) One year from grant
  • B) Two years from grant
  • C) Three years from grant
  • D) Five years from grant
Explanation:
Section 84(1) provides that at any time after the expiration of three years from the date of grant of a patent, any person interested may apply for a compulsory license. This gives the patentee time to commercialize the invention before compulsory licensing becomes available.
Question 4 of 10
In Natco v. Bayer, the compulsory license was granted because:
  • A) The drug was not reasonably affordable, reasonable requirements were not met, and it was not worked in India
  • B) Bayer's patent was invalid
  • C) There was a national emergency
  • D) Bayer refused to grant a voluntary license
Explanation:
The Controller found all three Section 84 grounds satisfied: the drug (priced at Rs. 2.8 lakh/month) was not reasonably affordable; Bayer supplied only 2% of patients needing it (reasonable requirements not met); and Bayer imported rather than manufactured in India (not worked in territory). Natco's generic was priced at Rs. 8,800/month.
Question 5 of 10
Section 107A(a) (Bolar Exception) permits:
  • A) Commercial sale of patented drugs
  • B) Acts reasonably related to development and submission of regulatory information
  • C) Export of patented drugs to any country
  • D) Use for any research purpose
Explanation:
Section 107A(a) specifically permits acts of making, constructing, using, selling, or importing a patented invention "solely for uses reasonably related to the development and submission of information required under any law" that regulates manufacture, sale, or import. This enables generic companies to prepare regulatory submissions before patent expiry.
Question 6 of 10
Data exclusivity in pharmaceuticals refers to:
  • A) Protection of clinical trial data from publication
  • B) Exclusive rights over patient data
  • C) Trade secret protection for formulations
  • D) Protection preventing regulators from relying on originator data to approve generics
Explanation:
Data exclusivity prevents regulatory authorities from relying on an originator's clinical trial data to approve generic versions for a specified period. This blocks generic approval even if no patent exists. India has not adopted data exclusivity, which is crucial for maintaining generic competition.
Question 7 of 10
The 2022 WTO TRIPS waiver decision for COVID-19 covers:
  • A) All COVID-19 health products including therapeutics and diagnostics
  • B) Only COVID-19 diagnostics
  • C) Only COVID-19 vaccines
  • D) COVID-19 vaccines and therapeutics but not diagnostics
Explanation:
The June 2022 WTO decision was limited to patents on COVID-19 vaccines only, not therapeutics or diagnostics as India and South Africa had proposed. The narrow scope was a compromise between proponents (developing countries) and opponents (developed countries and pharma industry) of the waiver.
Question 8 of 10
Biosimilars differ from traditional generics because:
  • A) They are highly similar but not identical to the original biologic
  • B) They are chemically identical to the original
  • C) They require no clinical testing
  • D) They can only be made by the original manufacturer
Explanation:
Biologics are large, complex molecules produced by living cells. Due to this complexity, biosimilars can be "highly similar" but not identical to the original. Process variations affect the product. This requires extensive comparative clinical trials rather than simple bioequivalence studies used for small-molecule generics.
Question 9 of 10
"Evergreening" in pharmaceutical patents refers to:
  • A) Developing environmentally sustainable drugs
  • B) Extending patent monopolies through incremental modifications
  • C) Filing patents in multiple countries
  • D) Manufacturing drugs using green chemistry
Explanation:
Evergreening is the practice of obtaining additional patents on minor modifications (new forms, salts, polymorphs, formulations) to extend the effective monopoly period beyond the original patent term. Section 3(d) was specifically designed to prevent this by requiring enhanced therapeutic efficacy for new forms.
Question 10 of 10
Section 92 permits compulsory licensing:
  • A) Only for export purposes
  • B) Only after failed voluntary license negotiations
  • C) Only after three years from grant
  • D) During national emergency or extreme urgency without the three-year waiting period
Explanation:
Section 92 allows the government to issue compulsory licenses during national emergency, extreme urgency, or for public non-commercial use. Unlike Section 84, there is no need to wait three years from grant or first attempt to negotiate a voluntary license. This enables rapid response to public health crises.